drugset / Trial / NCT04274075
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
RandomizedCrossoverOpen-labelBasic science
Summary
This study will be an open-label, randomized, three-period, six-sequence crossover study of GDC-9545 administered to healthy females of non-childbearing potential to determine the relative bioavailability of the Phase 3 capsule formulation to the Phase 1 tablet formulation in the fasted state and the effect of food on the Phase 3 capsule formulation.
Timeline
- Start
- 2020-03-06
- Primary completion
- 2020-04-16
- Completion
- 2020-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Giredestrant | Small molecule | 30 mg | Oral |
Indications
No indication recorded.